Comparison of the Efficacy of Paracetamol and Ibuprofen in the Management of Fever in Sepsis Patients

Sponsor
Ankara City Hospital Bilkent (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06061575
Collaborator
(none)
84
1
2
13
6.4

Study Details

Study Description

Brief Summary

This is a randomized double-blind controlled study with the primary aim of scientifically evaluating the potential effects of paracetamol and ibuprofen in the management of sepsis by comparing their fever-reducing efficacy in septic patients. Sepsis is recognized as a severe form of systemic inflammatory response syndrome (SIRS) characterized by organ dysfunction resulting from severe infections. This study aims to address a significant aspect of fever management in septic patients by objectively assessing the fever-reducing potential of paracetamol and ibuprofen.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

This is a randomized double-blind controlled study with the primary aim of scientifically evaluating the potential effects of paracetamol and ibuprofen in the management of sepsis by comparing their fever-reducing efficacy in septic patients. Sepsis is recognized as a severe form of systemic inflammatory response syndrome (SIRS) characterized by organ dysfunction resulting from severe infections. This study aims to address a significant aspect of fever management in septic patients by objectively assessing the fever-reducing potential of paracetamol and ibuprofen.

In addition to assessing the fever-reducing efficacy of paracetamol and ibuprofen, this study will also evaluate their ability to provide symptomatic relief. The effects of paracetamol and ibuprofen on vital signs in septic patients will be examined to understand the overall course of the clinical condition. The analysis of the side effect profile aims to provide a comprehensive view of the safety and tolerability of both drugs.

The significance of this study can be explained by the critical role of fever regulation in sepsis management. Commonly used drugs like paracetamol and ibuprofen are widely employed to reduce fever and alleviate symptoms. However, there is limited data regarding the efficacy and safety of these drugs in septic patients. This research will help us better understand the role of these drugs in fever management in septic patients and contribute to optimizing treatment strategies. The findings of this study may guide clinical practice and establish a stronger scientific foundation for the management of septic patients.

This research may bring a new perspective to clinical practices regarding fever management in septic patients. By providing scientific data on whether commonly used drugs like paracetamol and ibuprofen can contribute to sepsis treatment, it may enhance the more effective management of patients. If it is demonstrated that paracetamol and ibuprofen can be used effectively and safely in septic patients, treatment optimization can be achieved with appropriate dosages and under suitable conditions. This may enable patients to achieve more effective fever control.

The results of the research may offer a better scientific basis for the use of drugs like paracetamol and ibuprofen in septic patients in clinical settings.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
84 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Comparison of the Efficacy of Paracetamol and Ibuprofen in the Management of Fever in Sepsis Patients: A Randomized Double-Blind Controlled Study
Anticipated Study Start Date :
Oct 31, 2023
Anticipated Primary Completion Date :
Oct 31, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Other: Acetaminophen

Adult patients diagnosed with sepsis according to the latest current guidelines, who have agreed to participate in the study or have provided consent by their relatives, and received 1g of acetaminophen for fever management.

Drug: Acetaminophen
fever will be managed with acetaminophen
Other Names:
  • Acetaminophen 1gr
  • Other: Ibuprofen

    Adult patients diagnosed with sepsis according to the latest current guidelines, who have agreed to participate in the study or have provided consent by their relatives, and received 400 mg of ıbuprofen for fever management.

    Drug: Ibuprofen
    fever will be managed with ibuprofen
    Other Names:
  • Ibuprofen 400 mg
  • Outcome Measures

    Primary Outcome Measures

    1. Fever [30.-60.-120. minutes]

      Body temperature, celcius

    Secondary Outcome Measures

    1. Heart Rate [30.-60.-120. minutes]

      Heart rate per minute

    2. Blood Pressure [30.-60.-120. minutes]

      Systolic and diastolic blood pressure in mmHg

    3. Oxygen saturation [30.-60.-120. minutes]

      Measured as a percentage through capillary measurement

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 18 years of age or older

    • Under 80 years of age

    • Willing to participate in the study

    • Diagnosed with sepsis according to the latest current guidelines

    • Having a fever >38°C

    • With no known history of adverse reactions to the active ingredient of the medication to be used"

    Exclusion Criteria:
    • Under 18 years of age or over 80 years of age

    • Not willing to participate in the study

    • With a known history of adverse reactions to study medications

    • Having a fever <38°C

    • Pregnant individuals

    • Individuals with advanced systemic illness

    • Those with malignancies

    • Patients with chronic liver and kidney disease

    • Using sedative and analgesic neuro-psychiatric drugs

    • With a history of psychological and neurological diseases"

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ankara City Hospital Ankara Turkey 06800

    Sponsors and Collaborators

    • Ankara City Hospital Bilkent

    Investigators

    • Principal Investigator: SAFA DÖNMEZ, M.D., Ankara Bilkent City Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Safa Dönmez, M.D., Ankara City Hospital Bilkent
    ClinicalTrials.gov Identifier:
    NCT06061575
    Other Study ID Numbers:
    • Management of Fever in Sepsis
    First Posted:
    Sep 29, 2023
    Last Update Posted:
    Sep 29, 2023
    Last Verified:
    Sep 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 29, 2023